TOMY Boon Highchair Recall Issued After Dozens of Falls, Infant Injuries

The manufacturer has received numerous reports of the highchairs separating from their bases, resulting in the chairs, and the children in them, falling over.

More than 85,000 TOMY highchairs have been recalled, following reports of problems where the seat suddenly separated from the pedestal base, resulting in at least two dozen incidents where children fell from the highchairs, often suffering injuries, bruises and scratches.

The U.S. Consumer Product Safety Commission (CPSC) announced the TOMY highchair recall on August 31, indicating that the bolts used to secure the seat to the pedestal base can become loose and allow the seat to detach. This can pose a fall hazard to the child occupant inside.

TOMY has received 34 reports of the chair separating from the base, which has resulted in reports of at least 24 falls and 11 child injuries.

The recall includes Boon Flair highchairs manufactured before September 2016 and all Boon Flair Elite highchairs manufactured at any time. The Flair Elite has a white and orange molded plastic seat with a white tray and metal pedestal base. Flair highchairs have a gray plastic pedestal base and were sold in 10 color combinations, including blue/white, white/orange, pink/white, green/white, gray/green, white, gray, white/gray, white/blue, and red/white. The recall includes model numbers B751, B701–B709, B716–B718, B731, B10147, B11068, B11069, and B11401.

Consumers can check the model number and manufacturing date code printed on the label located under the base of the highchair.

According to the recall notice, about 83,000 of the recalled highchairs were sold in the U.S., with another 2,850 sold in Canada. They were manufactured in China and distributed by TOMY, based in Oak Brook, Illinois.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The highchairs were sold at Bed Bath & Beyond, Target, Toys ‘R’ Us, and other stores nationwide, as well as online at Amazon.com, Target.com, Walmart.com, and BedBathAndBeyond.com.

Flair Elite highchairs were sold from 2008 to 2009 for about $380. The Flair models were sold from January 2008 through February 2017 for between $230 and $250.

The CPSC recommends consumers stop using the affected highchairs immediately and contact TOMY for a free repair kit. The repair kit will include a set of bolts and split and flat washers to repair the recalled highchair.

Consumers with questions about the recall should contact TOMY at 866-725-4407 or online at https://recall.tomy.com.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.